• Home
  1. Home
  2. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study
Scientific article
OA Policy
English

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

ContributorsBridel, Claireorcid; Beauverd, Yan; Samii, Kaveh; Lalive d'Epinay, Patrice
Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 4, e123
Publication date2015
Abstract

To monitor the hematologic modifications in the peripheral blood of patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Affiliation entities
Research groups
Citation (ISO format)
BRIDEL, Claire et al. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 4, p. e123. doi: 10.1212/NXI.0000000000000123
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN2332-7812
493views
392downloads

Technical informations

Creation27/01/2016 11:50:00
First validation27/01/2016 11:50:00
Update15/03/2023 00:23:50
Status update15/03/2023 00:23:50
Last indexation31/10/2024 03:30:53
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack